Kalkine has a fully transformed New Avatar.

Control Bionics Ltd

Healthcare AU CBL

0.031AUD
0.001(3.33%)

Last update at 2025-06-13T05:59:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.030.10
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap8.84M
  • Volume247510
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.99917M
  • Revenue TTM5.28M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 3.56M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -5.91378M -5.63114M -6.10122M -3.55083M -1.10848M
Minority interest - - - - -
Net income -5.91378M -5.63114M -6.11011M -4.18768M -1.00550M
Selling general administrative 5.67M 5.29M 4.91M 3.33M 0.79M
Selling and marketing expenses 0.46M 0.62M 0.71M 0.44M 0.25M
Gross profit 3.67M 3.50M 2.40M 2.50M 0.22M
Reconciled depreciation 0.84M 0.48M 0.51M 0.20M -
Ebit -5.85750M -5.61883M -6.09234M -3.59680M -1.10515M
Ebitda -5.01431M -5.13838M -5.58449M -3.39826M -0.98996M
Depreciation and amortization 0.84M 0.48M 0.51M 0.20M 0.12M
Non operating income net other - - - - -
Operating income -5.92927M -5.61883M -6.09234M -3.51805M -1.20410M
Other operating expenses 11.28M 11.72M 10.99M 8.01M 4.30M
Interest expense 0.06M 0.01M 0.00889M 0.03M 0.00333M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.01M 0.02M 0.00133M 0.00116M 0.00333M
Net interest income -0.04410M -0.00119M -0.04167M -0.06921M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.85040M 0.67M 0.00889M 0.64M -0.10298M
Total revenue 5.13M 5.44M 4.38M 3.93M 3.10M
Total operating expenses 9.83M 9.79M 9.01M 6.58M 1.42M
Cost of revenue 1.45M 1.93M 1.98M 1.43M 2.88M
Total other income expense net 0.02M -0.42495M -0.08752M -0.60071M 0.10M
Discontinued operations - - - - -
Net income from continuing ops -5.91378M -5.63114M -6.10122M -3.55083M -
Net income applicable to common shares - -5.63114M -6.10122M -3.55083M -1.00550M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 9.03M 8.70M 13.44M 18.35M 20.51M
Intangible assets - 4.11M 4.07M 4.08M 4.08M
Earning assets - - - - -
Other current assets 0.19M 0.20M 0.71M 0.11M 0.12M
Total liab 2.76M 1.55M 1.51M 1.19M 0.39M
Total stockholder equity 6.27M 7.15M 11.92M 17.16M 20.13M
Deferred long term liab - - - - -
Other current liab 0.85M 0.89M 0.77M 0.70M 0.00100M
Common stock 35.15M 30.24M 29.27M 28.17M 27.64M
Capital stock - 30.24M 29.27M 28.17M 27.64M
Retained earnings -29.27916M -23.36538M -17.73424M -11.63301M -8.25700M
Other liab - 0.02M 0.03M 0.02M 0.01M
Good will - - - - -
Other assets - 0.00000M 0.02M 0.02M 0.05M
Cash 0.98M 0.94M 5.21M 12.33M 15.60M
Cash and equivalents - - - - -
Total current liabilities 2.40M 1.53M 1.36M 1.17M 0.36M
Current deferred revenue 0.32M - - - 0.14M
Net debt -0.01902M -0.80700M -4.92918M -12.31624M -15.55000M
Short term debt 0.63M 0.13M 0.16M 0.01M 0.04M
Short long term debt - - 0.05M - -
Short long term debt total 0.96M 0.13M 0.28M 0.01M 0.05M
Other stockholder equity - 0.09M 0.39M 0.62M 0.75M
Property plant equipment - 0.72M 0.71M 0.53M 0.29M
Total current assets 3.76M 3.87M 8.61M 13.72M 16.09M
Long term investments - - - - -
Net tangible assets - 3.04M 7.83M 13.08M 1.64M
Short term investments - - - - -
Net receivables 2.19M 1.78M 1.76M 1.12M 0.32M
Long term debt - - - 0.00000M 0.24M
Inventory 0.40M 0.80M 0.92M 0.27M 0.18M
Accounts payable 0.61M 0.52M 0.43M 0.46M 0.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.39M 0.27M 0.39M 0.62M 0.75M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.05M - 0.02M 0.02M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 5.27M 4.83M 4.83M 4.63M 4.42M
Capital lease obligations - 0.13M 0.24M 0.01M 0.05M
Long term debt total - 0.00000M 0.12M 0.00000M 0.25M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.47309M -0.45754M -0.14774M -0.05340M -
Change to liabilities - 0.32M -0.01436M 0.44M 0.20M
Total cashflows from investing activities - -0.45754M -0.14774M -0.05340M -0.30185M
Net borrowings - -0.15632M -0.04518M -0.04521M 0.21M
Total cash from financing activities 5.43M 0.71M -0.08732M 14.92M 1.79M
Change to operating activities - -0.31441M 0.06M 0.03M -0.09131M
Net income -5.91378M -5.63114M -6.11011M -3.55083M -1.00550M
Change in cash 0.05M -4.27850M -7.11711M 10.90M 0.63M
Begin period cash flow 0.94M 5.21M 12.33M 1.43M 0.80M
End period cash flow 0.98M 0.94M 5.21M 12.33M 1.43M
Total cash from operating activities -4.91190M -4.52739M -5.60226M -3.99063M -0.86405M
Issuance of capital stock 5.09M 0.75M 0.01M 15.68M -
Depreciation 0.84M 0.48M 0.51M 0.20M 0.12M
Other cashflows from investing activities -0.07475M -0.03742M - -0.00524M -0.00702M
Dividends paid - - - 0.05M -
Change to inventory -0.04842M 0.12M -0.65458M -0.09005M 0.00112M
Change to account receivables -0.76055M -0.23533M -0.41546M -0.80406M -0.02749M
Sale purchase of stock -0.11448M 0.86M 0.01M -0.71529M 1.58M
Other cashflows from financing activities -0.06923M 0.81M -0.00799M -0.04521M 1.58M
Change to netincome - 0.74M -0.27359M -0.21579M -0.05602M
Capital expenditures 0.47M 0.46M 0.15M 0.05M 0.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.46264M -0.11184M -1.01997M -0.42255M -0.11768M
Stock based compensation 0.14M 0.04M 0.05M 0.09M 0.05M
Other non cash items 0.62M 1.49M 5.60M 0.63M 0.26M
Free cash flow -5.38499M -4.98493M -5.75000M -4.04403M -1.16590M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CBL
Control Bionics Ltd
0.001 3.33% 0.03 - - 1.67 1.41 1.70 -2.2282
COH
Cochlear Ltd
0.54 0.20% 272.85 47.77 38.76 7.65 9.44 7.58 29.28
PNV
Polynovo Ltd
-0.085 6.72% 1.18 126.50 147.06 7.56 11.58 7.45 93.59
IMR
Imricor Medical Systems Inc
-0.065 3.86% 1.62 - - 564.46 3.97 374.91 -2.6027
EBR
Ebr Systems Inc CDR
-0.09 7.56% 1.10 - - - 19.90 -3.6785

Reports Covered

Stock Research & News

Profile

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; and NeuroNode Duo, a wireless sensor. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.

Control Bionics Ltd

11-13 Pearson Street, Cremorne, VIC, Australia, 3121

Key Executives

Name Title Year Born
Mr. Peter Shann Ford Founder, Interim CEO, Exec. Director & Director of Innovation NA
Mr. Robert William Wong Exec. Director NA
Mr. Todd Tyler US Country Mang. NA
Dominik Kucera Interim Chief Financial Officer NA
Mr. James Schorey Chief Technology Officer NA
Ms. Meagan Koeneman Sales Director NA
Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw Company Sec. 1957
Mr. Jeremy E. Steele CEO, MD & Director NA
Mr. Peter Shann Ford Founder & Non-Executive Director NA
Mr. Dominik Kucera Interim Chief Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.